Hot Investor Mandate 4: Investment Firm with Offices in USA, China, and India Invests Opportunistically in Life Sciences, with Strongest Interest in Novel Medical Devices and Cardiovascular Diseases

Founded in 2015, is a venture capital firm with offices in Boston, China, and India currently manages a fund with $125 million and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Use RESI Innovation Challenge As Part of Your Global Marketing Plan

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Market Your Life Science Startup to Investors

life science nation marketing

A fundraising campaign starts with presenting yourself and your technology to potential channel partners and investors who are a fit for your product and stage of development. As part of the Redefining Early Stage Investments (RESI) Conference, attendees can apply to the RESI Innovation Challenge which, if you are selected to participate, can greatly increase exposure for your company before, during and after the day of the conference. The partners and investors who frequent RESI know that the companies selected, routinely showcase compelling technology. Attending RESI and participating in the RESI Innovation Challenge are only one part of fundraising for CEOs and scientist-entrepreneurs. Here is Life Science Nation’s step-by-step process for a successful fundraising campaign and how and why RESI plays an important role.

 

Step 1: You need a list of investors and contacts

To raise capital, an early-stage CEO needs to create a Global Target List of potential investors. There are around 400-500 relevant global early-stage investors on a typical Global Target List, spanning 10 categories of investors in early-stage Biotech, Medtech, Diagnostics, and Digital Health. This list should be sourced from a curated platform to ensure the most up-to-date information. With a vetted list of qualified investors who are a fit, the fundraising executive can be more efficient in their outreach. This will lead to a higher response rate from your phone and email campaigns and thus result in a higher number of meetings booked to initiate dialogue with your partnering targets.

Step 2: Hire the right people

A fundraising campaign is something your company can execute internally with the right staff: phoning and emailing investors, setting up meetings, and organizing the campaign follow-up takes an enthusiastic personality. While many CEOs might be tempted to look for an outside service provider to manage the fundraising campaign, my recommendation is to do it internally. Personal outreach and clear messaging are equally important when reaching out to potential investors. At the end of the day, fundraising is a numbers game and having the right staff canvassing your Global Target List and initiating dialogue causes relationships to take root. However, initiating the conversation is never enough – the follow-ups, second and third meetings are when you’re generating real interest. This requires dedicated effort to ensure proper follow-through.

Step 3: Join opportunities to network

Face-to-face meetings are best for promoting relationships – that’s why we’ve created the RESI Conference. If you come to our next RESI, you may find 20-30% of your targeted investment firms are attending to find the earliest and hottest innovators within the healthcare industry. We offer one-on-one partnering all day for all global attendees at our Partnering Forum. By taking full advantage of our Partnering Platform, you have the opportunity to schedule one-on-one meetings with up to 16 of these investors, supplemented by ad hoc meetings, especially if you are a participant in the RESI Innovation Challenge.

 

the life science executive's fundraising manifesto by dennis ford

Want to learn more about fundraising?

If you read my free book The Life Science Executive’s Fundraising Manifesto, you will see that I am a big proponent of getting a complete Global Target List and then working the whole list. Establish a dialogue, go to RESI or other events and meet them–you must network. Follow up regularly by emailing all the targets with news on your company and how it is reaching milestones and getting compelling data: investor updates are key to your success and their vested interest in your company.

If you market to this list in an adroit and cogent way you will get on the investors’ radar screen. It’s a numbers game, and when you market to your Global Target List consistently you never know who will surface and what opportunities may arise. If you are just sending out material to investors who are attending an event, why not send out to all who are a potential fit for you? It only takes one interested investor to move a deal along.

It’s hard for fundraising CEOs to avoid cutting corners to save a few thousand dollars on campaign costs, but this can lead to a lot of missed opportunities. Putting your company out there as much as possible by investing in a high-quality marketing package and web presence, hiring staff who can conduct a campaign, and traveling to major investment events will maximize your odds of getting funded.

In addition, being selected as a participant in the RESI innovation Challenge has a compelling track record of helping companies get funded. The deadline to sign up for the RESI Innovation Challenge is soon! Click here to sign up.

Additional resources LSN has created for fundraising CEOs:

[Article] When Raising Capital, CEOs Should Understand the LSN Value Proposition

[Video] “The 10 Myths of Fundraising” Presentation at Freemind Group’s Non-Dilutive Funding Summit

[Article] Life Science Nation Ecosystem – A Matching Platform for Buyers and Sellers

[Book Chapter] LSN Summer Reading Series Chapter 9: “Global Target List—Match Your Firm with Investors That Are a Fit”

[Article] 10 Steps to a Life Science Fundraising Campaign

Hot Investor Mandate 1: Japanese Pharmaceutical Seeks to Partner with Global Innovations in Therapeutics, Devices, Digital Health with Focus in Orthopedics, Respiratory, Cardivascular Diseases

A pharmaceutical company headquartered in Tokyo, Japan, focuses on two main sectors: pharmaceutical and medical device for home healthcare. The company is seeking innovative medical technologies to strengthen its pipeline while expanding into new areas. The company is looking for in-licensing and collaborative R&D opportunities in the US, Canada, EU, and Israel.

The company has existing businesses in respiratory diseases, cardiovascular diseases, and orthopedics. The firm is seeking innovative, home-care, therapeutic medical devices in the disease sectors described above. The company is also interested in home patient monitoring products. In addition, the company is looking for innovations in the following areas: neurological disorders such as stroke, depression, Parkinson’s disease, etc.; cancer; wound care; and rehabilitation, which all must be used at home care. The company is most interested in PMA and de novo therapeutic devices in the home-care settings. The company prefers assets with initial patient data. Furthermore, the company is seeking opportunities in digital medicine business (but not for consumer products) in disease areas described above.

Within pharmaceuticals, the company had previously focused on late clinical stage assets in orthopedics, respiratory diseases, and cardiovascular diseases, but has expanded interests to consider early-stage opportunities. The company is most interested in small molecule and peptide drugs.

The company is looking for assets that are a compliment to its portfolio. The company prefers to own rights in the Japan market, while its partners can keep US or EU rights. The company’s regulatory team, clinical team and support system can assist its partners with product registration and distribution in Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Subsidiary of Large Pharmaceutical Looking for Innovative Therapeutic Companies Developing Treatments for Rare Blood Diseases

A fully owned subsidiary of a large pharmaceutical that focuses on treating rare blood diseases. The company partners with and invests in early stage companies in the blood disease field using a variety of structures. The company is open to partnering with companies worldwide.

The company is focused solely on rare blood diseases, including hemophilia, sickle cell disease, cold agglutinin disease, and beta thalassemia; the firm will consider assets in any rare blood disease, but does not consider blood cancers or blood-born pathogens. The company will consider assets from the very early idea stage through to commercial products. In addition to any therapeutic drugs that treat blood diseases, the company is also interested in other modalities such as medical devices, wearables and digital technologies that help treat or manage blood diseases.

The company is open to working with companies and researchers from a very early stage; for companies that do not yet have a complete management team, the company may take an active role in building a team or guiding development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Venture Capital Firm with Strong Connections to China Seeks to Invest in Global, Early-Stage Biotech Companies with Opportunistic Outlook

A venture capital firm founded in 2014 has an office in the West Coast with its parent company based in Hangzhou, China. The firm currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm is currently allocating out of its first fund of $20M and prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

The firm is currently raising a second fund with a target size of $50M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. Early in 2018, the firm has launched an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Healthtech Week Announces the First Coast Innovation Challenge on September 5th, And the RESI Global Innovation Challenge on September 6th

By Samuel Rubin, Business Development Manager, LSN

For the first time this fall, Life Science Nation (LSN) will have two days of competition as part of the RESI Healthtech Week (September 5-7, 2018). Day 1 will feature the First Coast Innovation Challenge, where the top 10 ranked companies of the First Coast tech hubs will present their technology as a 10-minute pitch to a panel of early-stage investors. Day 2 features the traditional RESI Innovation Challenge, where the top 30 companies who apply are chosen to showcase a poster on the RESI Global Partnering Conference Exhibit Hall.

LSN is proud to now include presentation opportunities for top technologies from the First Coast that have recently moved out of the lab and are ready to target grant, angel, and seed funding. The First Coast Innovation Challenge on Day 1 complements the RESI Global Innovation Challenge on Day 2, offering greater investor exposure to companies from the earliest stage to more established startups that are looking globally and seeking funding from institutional investors.

Applying for the Innovation Challenge at RESI Healthtech Week Will Boost Your Exposure with Investors

Those selected to be Innovation Challenge finalists will have the potential to dramatically increase the number of meaningful investor relationships they build. The objective of most early-stage companies and tech hubs attending RESI Healthtech Week is to have one-on-one meetings with investors who are a fit for them. The Innovation Challenge expands on the RESI Partnering Forum, providing an avenue to directly showcase to the whole investor audience, in addition to booking formal one-on-one meeting opportunities. Investors attending RESI Healthtech Week know that Innovation Challenge finalists are selected based on credentials for success and will be inclined to engage with these companies.

First Coast Innovation Challenge VS RESI Global Innovation Challenge

All registered attendees who qualify for Day 1 – First Coast Innovation Challenge are also eligible to apply for Day 2 – RESI Global Innovation Challenge. You must be a Qualifying First Coast Day 1 registrant to apply for the First Coast Innovation Challenge.

Qualifying Day 1 First Coast Innovation Challenge participants are the constituents of northeast corridor incubators, accelerators, tech transfer offices, university translation initiatives, hospitals, and research labs. Day 2 is open to all global attendees – scientist-entrepreneurs, fundraising CEOs, and the First Coast.

Selected finalists on Day 1 will pitch to global investors, while the selected Day 2 finalists will showcase their poster in the exhibit hall and will be eligible for the prizes awarded to the top Day 2 participants.

Innovation Challenge Application Open Now!

The online application for the Innovation Challenge officially opens today! We welcome applications both for Day 1 – First Coast Innovation Challenge, and Day 2 – RESI Global Innovation Challenge. The application deadline is Friday July 27, 2018 for both competitions.

If you are accepted as a finalist, we will notify you by Thursday August 9th, and you will have until Thursday August 16th to confirm your participation and register for RESI Healthtech Week.

The LSN Review Team and the 300+ investors attending RESI Healthtech Week look forward to learning more about your unique technologies!

 

 

Hot Investor Mandate 4: Corporate Venture Arm of Global Pharma Seeks Therapeutics Companies with Focus on Pre-IND Assets in All Indications

A financially driven corporate life science venture fund of a global pharmaceutical company, invests with the purpose of fostering innovation, driving significant patient benefit, and generating superior returns by creating and investing in innovative life science companies at various stages of their development, independent from the corporate’s strategy. The firm has offices in USA and Europe, and focuses its investment activities in these countries. The firm typically makes equity investments in early venture rounds, investing up to $25 million over multiple financing rounds with 6-8 investments in any given year.

The firm invests in therapeutics with a focus on pre-IND assets and Series A investment rounds. The firm is interested in all classes and indications of innovative therapeutics with paradigm shifting potential.

The firm invests exclusively in privately held companies and aims to be a lead or co-lead with a director position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.